How One Canadian Company Is Transforming the Future of Behavioral Health Across America
In the midst of a behavioral health crisis and a growing demand for alternative treatment options, Delic Holdings Corp. is betting big on the future of psychedelic therapy. The Vancouver-based company—trading publicly on the Canadian Securities Exchange and over the counter in the U.S.—is fast becoming a household name in the world of psychedelic wellness expansion.
In September 2021, Delic made headlines when it announced the acquisition of Ketamine Wellness Centers Arizona LLC (KWC) in a $10 million deal. With the acquisition finalized in November, Delic officially became the largest psychedelic wellness chain in the United States, with 10 new clinics across nine states: Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, Utah, and Washington.
This strategic move is more than just a milestone in market share—it marks a turning point in the broader movement toward psychedelic wellness expansion in the U.S., as public interest, patient demand, and clinical evidence align to create fertile ground for rapid growth.
Scaling Up: Clinics, Revenue, and Reach
The addition of KWC’s operations brought Delic’s projected pro forma annual revenue to over $8 million, thanks in part to KWC’s anticipated $4.5 million in 2021. With this acquisition, Delic doesn’t just grow in size—it becomes a leader in a sector poised to transform mental health care for millions.
And the growth doesn’t stop there.
Delic has announced plans to open 15 more clinics in the next 18 months, part of a nationwide rollout that will bring it within a 30-minute drive of half the U.S. population. This aggressive approach to psychedelic wellness expansion underscores Delic’s mission to make transformative treatments like ketamine therapy more widely available and affordable.
According to CEO and co-founder Matt Stang, the goal is simple: “We want this to be accessible to everyone. Not just the 1%.”
Redefining the Psychedelic Treatment Experience
A visit to one of Delic’s clinics reveals a process that is both medically rigorous and human-centered. Patients undergo a pre-screening process that includes interviews with clinicians and a medical evaluation to determine suitability for ketamine therapy.
Once cleared, patients are welcomed into a serene, sensory-calming environment where an IV ketamine infusion is administered in a quiet room with soft lighting, comfortable seating, and ambient music. The entire experience—from infusion to recovery—is supervised by licensed clinical staff.
Each site follows a standard operating procedure designed to ensure safety, consistency, and therapeutic value. With over 85,000 infusions performed across their network, Delic brings data-backed practices to every clinic—a key pillar in its strategy for psychedelic wellness expansion.
Making Access and Affordability Central to the Mission
Unlike competitors that focus on boutique clinics in high-end markets, Delic is intentionally building its footprint in large, accessible, cost-effective cities. From Phoenix to Salt Lake City, the company is placing clinics in locations that serve a broader and more diverse population.
“We’re not interested in chasing prestige markets like New York or L.A.,” Stang explained. “We’re building where people can actually afford to get the care they need.”
This accessibility focus is especially evident in the company’s partnership with the U.S. Department of Veterans Affairs’ Community Cares Network. Veterans in Illinois and Minnesota now have access to free ketamine treatments at Delic clinics—part of a larger initiative to address the rising mental health needs of those who have served.
This kind of public-private collaboration signals a larger shift in how psychedelic wellness expansion can reach vulnerable populations beyond the traditional healthcare system.
Building a Foundation for Long-Term Growth
Each Delic clinic operates under the supervision of a licensed physician, with either a nurse practitioner or registered nurse administering the therapy depending on state regulations. This decentralized but standardized approach allows Delic to navigate regulatory differences across states while maintaining consistency in care.
These measures are critical as Delic scales its model and navigates a complex and still-evolving regulatory landscape. Stang emphasizes that this isn’t just about growth for growth’s sake—it’s about building a trusted brand with credibility and longevity.
With a growing national footprint, rigorous medical protocols, and a clear mission, Delic is carving out a space as not only a healthcare provider but also a leader in responsible psychedelic wellness expansion.
Delic Labs: The Research Engine Behind the Brand
Beyond clinics, Delic is also investing in the future of psychedelic medicine through Delic Labs, its Vancouver-based research and development facility. Licensed by Health Canada, Delic Labs serves both as a proprietary research center and a contract research organization (CRO) for third-party clients.
“We have about 20 clients who rely on us to conduct psychedelic and cannabinoid research,” Stang noted. “And we’re also developing our own intellectual property.”
Delic Labs is exploring novel formulations, delivery methods, and new compounds—all part of the company’s long-term plan to stay ahead of the curve in a field ripe with opportunity. This dual strategy—clinical rollout and R&D—is core to Delic’s blueprint for sustainable psychedelic wellness expansion.
Preparing for the Next Generation of Psychedelic Treatments
While ketamine is currently the only FDA-approved psychedelic substance used in treatment, other compounds are on the horizon. MDMA is in phase 3 clinical trials and could be approved for PTSD therapy within the next two years. Psilocybin, too, is gaining traction in research and decriminalization movements across the country.
Delic is designing its infrastructure to be “molecule agnostic”—able to accommodate multiple psychedelic therapies as they become legal. The company’s vision is to be the go-to clinical provider for any and all approved psychedelic treatments in the U.S.
“What we’re building is a large chain of specialty clinics that can handle any form of psychedelic therapy,” said Stang. “That’s the future of psychedelic wellness expansion.”
Breaking Stigma: Reframing the Narrative Around Psychedelics
Public perception is another barrier Delic is actively working to overcome. The psychedelic compounds now being used in clinical therapy were once synonymous with counterculture and rebellion—often caricatured in popular media as “hippie drugs.”
Stang acknowledges this legacy but insists that the narrative is changing. “There’s been a seismic shift in the last decade. People are starting to see these substances not as escapism, but as powerful tools for reintegration and healing.”
Indeed, growing clinical data supports ketamine and other psychedelics as promising treatments for depression, PTSD, anxiety, and even substance use disorders. Delic is helping to lead this rebranding—not just through marketing, but through clinical outcomes, community partnerships, and public education.
This cultural work is an essential component of psychedelic wellness expansion, and Delic is approaching it with the same seriousness as its clinical efforts.
Looking Forward: From Niche to Normal
Today, Delic may still be viewed as a “niche” healthcare provider. But with every new clinic, every patient served, and every research breakthrough, that niche is becoming the new normal.
In the coming years, Delic aims to list on larger U.S. stock exchanges such as Nasdaq or the New York Stock Exchange, expand its presence to 30+ clinics, and continue driving innovation through Delic Labs.
But for Stang, the ultimate goal is personal: “My wife struggled with anxiety, and ketamine therapy changed our lives. If I can help just one other family go through the same transformation, it’s all worth it.”
That kind of emotional investment is part of what makes Delic’s brand of psychedelic wellness expansion so compelling—it’s not just about bottom lines. It’s about changing lives.
Final Thoughts: Building a Future in Psychedelic Medicine
Delic Holdings has rapidly grown from a startup with a bold idea to the largest provider of psychedelic wellness care in the United States. Through strategic acquisitions, a commitment to accessibility, and a foundation of clinical excellence, the company is redefining the boundaries of modern behavioral health.
As the regulatory landscape evolves and public awareness increases, Delic is poised to play a central role in the psychedelic wellness expansion movement for years to come. With a robust clinical model, cutting-edge R&D, and a leadership team driven by personal purpose, the company is more than ready to meet the moment—and lead the way.
